Brief: Iveric Bio Announces FDA Has Granted Therapy Designation For Avacincaptad Pegol
17/11/2022 22:20
Nov 17 (Reuters) - Iveric Bio Inc ISEE.O :
* IVERIC BIO ANNOUNCES FDA HAS GRANTED BREAKTHROUGH THERAPY
DESIGNATION FOR AVACINCAPTAD PEGOL FOR GEOGRAPHIC ATROPHY
* IVERIC BIO INC - COMPANY IS ON TRACK TO COMPLETE FINAL
PART OF
NDA SUBMISSION BY END OF THIS YEAR
Source text for Eikon: ID:nBw15cG5ga
Further company coverage: ISEE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IVERIC bio
See all newsBrief: Astellas Pharma Inc - Astellas Completes Acquisition Of Iveric Bio
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
Iveric Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
The end of cheap credit could hurry Japanese M&A
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini